pioglitazone has been researched along with Osteoarthritis in 7 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Osteoarthritis: A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aims of this study were to assess the anti-degenerative effects of pioglitazone and to compare these effects with those of methylprednisolone and hyaluronic acid on drug-induced osteoarthritis in rabbits' temporomandibular joint cartilage." | 7.83 | Effect of methylprednisolone, hyaluronic acid and pioglitazone on histological remodeling of temporomandibular joint cartilage in rabbits affected by drug-induced osteoarthritis. ( Kałużyński, K; Masiuk, M; Myśliwiec, L; Smektała, T; Sporniak-Tutak, K; Trybek, G, 2016) |
| "To evaluate the in vivo therapeutic effect of pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, on the development of lesions in a guinea pig model of osteoarthritis (OA), and to determine the influence of pioglitazone on the synthesis of matrix metalloproteinase 13 (MMP-13) and interleukin-1beta (IL-1beta) in articular cartilage." | 7.73 | Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. ( Kobayashi, T; Martel-Pelletier, J; Naito, T; Nakamura, A; Notoya, K; Pelletier, JP; Unno, S, 2005) |
| "Pioglitazone reduced the development of cartilage lesions in a dose-dependent manner, with the highest dosage producing a statistically significant change (P < 0." | 5.34 | The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: in vivo protective effects mediated through the inhibition of key signaling and cataboli ( Boileau, C; Boily, M; Fahmi, H; Martel-Pelletier, J; Mineau, F; Pelletier, JP, 2007) |
| "The aims of this study were to assess the anti-degenerative effects of pioglitazone and to compare these effects with those of methylprednisolone and hyaluronic acid on drug-induced osteoarthritis in rabbits' temporomandibular joint cartilage." | 3.83 | Effect of methylprednisolone, hyaluronic acid and pioglitazone on histological remodeling of temporomandibular joint cartilage in rabbits affected by drug-induced osteoarthritis. ( Kałużyński, K; Masiuk, M; Myśliwiec, L; Smektała, T; Sporniak-Tutak, K; Trybek, G, 2016) |
| "To evaluate the in vivo therapeutic effect of pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, on the development of lesions in a guinea pig model of osteoarthritis (OA), and to determine the influence of pioglitazone on the synthesis of matrix metalloproteinase 13 (MMP-13) and interleukin-1beta (IL-1beta) in articular cartilage." | 3.73 | Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. ( Kobayashi, T; Martel-Pelletier, J; Naito, T; Nakamura, A; Notoya, K; Pelletier, JP; Unno, S, 2005) |
| "Pioglitazone reduced the development of cartilage lesions in a dose-dependent manner, with the highest dosage producing a statistically significant change (P < 0." | 1.34 | The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: in vivo protective effects mediated through the inhibition of key signaling and cataboli ( Boileau, C; Boily, M; Fahmi, H; Martel-Pelletier, J; Mineau, F; Pelletier, JP, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J | 1 |
| Xu, W | 1 |
| Dai, T | 1 |
| Jiao, S | 1 |
| Xue, X | 1 |
| Jiang, J | 1 |
| Li, S | 1 |
| Meng, Q | 1 |
| Ding, LB | 1 |
| Li, Y | 1 |
| Liu, GY | 1 |
| Li, TH | 1 |
| Li, F | 1 |
| Guan, J | 1 |
| Wang, HJ | 1 |
| Kałużyński, K | 1 |
| Trybek, G | 1 |
| Smektała, T | 1 |
| Masiuk, M | 1 |
| Myśliwiec, L | 1 |
| Sporniak-Tutak, K | 1 |
| Zhang, HB | 1 |
| Zhang, Y | 2 |
| Chen, C | 2 |
| Li, YQ | 1 |
| Ma, C | 1 |
| Wang, ZJ | 1 |
| Yang, Q | 1 |
| Wu, S | 1 |
| Mao, X | 1 |
| Wang, W | 1 |
| Kobayashi, T | 1 |
| Notoya, K | 1 |
| Naito, T | 1 |
| Unno, S | 1 |
| Nakamura, A | 1 |
| Martel-Pelletier, J | 2 |
| Pelletier, JP | 2 |
| Boileau, C | 1 |
| Fahmi, H | 1 |
| Mineau, F | 1 |
| Boily, M | 1 |
7 other studies available for pioglitazone and Osteoarthritis
| Article | Year |
|---|---|
Pioglitazone-Loaded Cartilage-Targeted Nanomicelles (Pio@C-HA-DOs) for Osteoarthritis Treatment.
Topics: Animals; Cartilage, Articular; Chondrocytes; Hyaluronic Acid; Hydrogen Peroxide; Osteoarthritis; Pio | 2023 |
Long non-coding RNA PVT1, a molecular sponge of miR-26b, is involved in the progression of hyperglycemia-induced collagen degradation in human chondrocytes by targeting CTGF/TGF-
Topics: Aged; Cartilage; Chondrocytes; Collagen; Connective Tissue Growth Factor; Diabetes Mellitus; Female; | 2020 |
Effect of methylprednisolone, hyaluronic acid and pioglitazone on histological remodeling of temporomandibular joint cartilage in rabbits affected by drug-induced osteoarthritis.
Topics: Animals; Anti-Inflammatory Agents; Cartilage, Articular; Hyaluronic Acid; Injections, Intra-Articula | 2016 |
Pioglitazone inhibits advanced glycation end product-induced matrix metalloproteinases and apoptosis by suppressing the activation of MAPK and NF-κB.
Topics: Animals; Apoptosis; Caspase 3; Chondrocytes; Glycation End Products, Advanced; Humans; Male; MAP Kin | 2016 |
Advanced glycation end products downregulates peroxisome proliferator-activated receptor γ expression in cultured rabbit chondrocyte through MAPK pathway.
Topics: Animals; Cartilage, Articular; Cells, Cultured; Chondrocytes; Enzyme Activation; Gene Expression Reg | 2010 |
Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs.
Topics: Administration, Oral; Animals; Cartilage, Articular; Collagenases; Disease Models, Animal; Disease P | 2005 |
The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: in vivo protective effects mediated through the inhibition of key signaling and cataboli
Topics: Animals; Cartilage; Disease Models, Animal; Dogs; Femur; Hypoglycemic Agents; Osteoarthritis; Piogli | 2007 |